ES2774491T3 - Terapia génica con insulina basada en hepatocitos para la diabetes - Google Patents

Terapia génica con insulina basada en hepatocitos para la diabetes Download PDF

Info

Publication number
ES2774491T3
ES2774491T3 ES17198106T ES17198106T ES2774491T3 ES 2774491 T3 ES2774491 T3 ES 2774491T3 ES 17198106 T ES17198106 T ES 17198106T ES 17198106 T ES17198106 T ES 17198106T ES 2774491 T3 ES2774491 T3 ES 2774491T3
Authority
ES
Spain
Prior art keywords
vector
insulin
use according
mammal
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17198106T
Other languages
English (en)
Spanish (es)
Inventor
Tausif Alam
Hans Sollinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of ES2774491T3 publication Critical patent/ES2774491T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
ES17198106T 2011-06-07 2012-06-06 Terapia génica con insulina basada en hepatocitos para la diabetes Active ES2774491T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161494134P 2011-06-07 2011-06-07

Publications (1)

Publication Number Publication Date
ES2774491T3 true ES2774491T3 (es) 2020-07-21

Family

ID=46246296

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17198106T Active ES2774491T3 (es) 2011-06-07 2012-06-06 Terapia génica con insulina basada en hepatocitos para la diabetes
ES12727062.7T Active ES2658487T3 (es) 2011-06-07 2012-06-06 Terapia génica con insulina basada en hepatocitos para la diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12727062.7T Active ES2658487T3 (es) 2011-06-07 2012-06-06 Terapia génica con insulina basada en hepatocitos para la diabetes

Country Status (6)

Country Link
US (6) US20120315255A1 (enExample)
EP (2) EP2718319B1 (enExample)
CA (1) CA2836921C (enExample)
ES (2) ES2774491T3 (enExample)
NO (1) NO2718319T3 (enExample)
WO (1) WO2012170531A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718319T3 (enExample) * 2011-06-07 2018-05-05
WO2013143698A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
EP3337402B1 (en) 2015-08-20 2026-01-07 Glytec, LLC Diabetes management therapy advisor
WO2020025357A1 (en) * 2018-08-02 2020-02-06 Novozymes A/S Preparation of combinatorial libraries of dna constructs using introns
CN120349985A (zh) * 2018-10-12 2025-07-22 建新公司 通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
TW202302858A (zh) * 2021-03-16 2023-01-16 威斯康辛校友研究基金會 治療糖尿病之胰島素基因療法
CA3252672A1 (en) * 2022-05-09 2023-11-16 Endsulin, Inc. VARIANT OF PREPROINSULIN AND CONSTRUCTIONS FOR INSULIN EXPRESSION AND THE TREATMENT OF DIABETES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427940A (en) 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5534404A (en) 1993-12-10 1996-07-09 Cytotherapeutics, Inc. Glucose responsive insulin secreting β-cell lines and method for producing same
US7425443B2 (en) 1997-01-21 2008-09-16 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
US6352857B1 (en) 1997-01-21 2002-03-05 Wisconsin Alumni Research Foundation Treatment of diabetes with synthetic beta cells
US8021875B2 (en) * 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
WO2007127408A2 (en) 2006-04-28 2007-11-08 Tulane University Health Sciences Center Methods for treating diabetes
DE102008042352A1 (de) 2008-09-25 2010-04-08 Robert Bosch Gmbh Ansteuerung eines Synchrongleichrichters
NO2718319T3 (enExample) * 2011-06-07 2018-05-05

Also Published As

Publication number Publication date
NO2718319T3 (enExample) 2018-05-05
WO2012170531A1 (en) 2012-12-13
US20140170123A1 (en) 2014-06-19
US20260117250A1 (en) 2026-04-30
EP2718319A1 (en) 2014-04-16
US10443072B2 (en) 2019-10-15
US20190382791A1 (en) 2019-12-19
ES2658487T3 (es) 2018-03-12
EP2718319B1 (en) 2017-12-06
US12163147B2 (en) 2024-12-10
CA2836921C (en) 2020-08-18
US20120315255A1 (en) 2012-12-13
EP3293197A1 (en) 2018-03-14
EP3293197B1 (en) 2020-01-08
US9732356B2 (en) 2017-08-15
CA2836921A1 (en) 2012-12-13
US20210388381A1 (en) 2021-12-16
US20170342441A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
US12163147B2 (en) Hepatocyte based insulin gene therapy for diabetes
US20020065239A1 (en) Methods and compositions for treatment of diabetes and related conditions via gene therapy
RU2014142994A (ru) Молекулы искусственной нуклеиновой кислоты
US20040132679A1 (en) Induction of pancreatic islet formation
Tasyurek et al. GLP-1-mediated gene therapy approaches for diabetes treatment
JP2002320490A (ja) 糖尿病治療用単鎖インスリン類似体およびその遺伝子を含むベクター
CN102209784B (zh) 骨膜素诱导的胰腺再生
JP2003526321A (ja) 合成ベータ細胞による糖尿病の治療
NZ575590A (en) In vivo transformation of pancreatic acinar cells into insulin-producing cells
Burkhardt et al. Glucose transporter‐2 (GLUT2) promoter mediated transgenic insulin production reduces hyperglycemia in diabetic mice
ES2304444T3 (es) Construcciones de acido nucleico utiles para la produccion regulada de glucosa de la insulina humana en las estirpes celulares somaticas.
Yasutomi et al. Intravascular insulin gene delivery as potential therapeutic intervention in diabetes mellitus
ES2267560T3 (es) Secuencias de adn para mejorar la eficacia de alimentacion y la tasa de crecimiento en cerdos.
US7425443B2 (en) Treatment of diabetes with synthetic beta cells
WO1995025169A1 (es) Gen quimerico que utiliza el gen o cdna de la insulina, en especial para terapia genica de la diabetes
Peroni et al. Animal models for growth hormone gene therapy
JPWO2009013794A1 (ja) インスリン分泌誘導剤及び膵臓β細胞増加促進剤
Handorf et al. Insulin Gene Therapy for Type 1 Diabetes Mellitus: Unique Challenges Require Innovative
US20240182925A1 (en) Insulin gene therapy to treat diabetes
CA2944186C (en) Gene-therapy vectors for treating cardiomyopathy
Yardeni et al. 144. A Non-Viral, GNE-Lipoplex Treatment to Correct Sialylation Defects in Gne-Mutant (M712T) Mice
Tafuro et al. 140. Gene Therapy Approaches Combining the Immunomodulatory Properties of Liver and IGF-I To Prevent Type I Diabetes
Peroni et al. Different ex Vivo and Direct in Vivo DNA Administration Strategies for Growth Hormone Gene Therapy in Dwarf Animals